Tarsus Pharmaceuticals, Inc. (TARS) Misses Q2 EPS by 10c

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q2 EPS of ($0.48), $0.10 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $102.7 million versus the consensus estimate of $95.68 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• USA Rare Earth (USAR) files for 126.5M share offering by selling stockholders
• CORVEX (MOVE) files $500M mixed shelf